### MAY - 3 2000

#### Attachment 4

## **Summary of Safety and Effectiveness**

General Provisions	Trade Name: Cordis Tempo™ Aqua Angiography Catheter	
	Common/Classification Name: Diagnostic Intravascular Catheter	
Name of Predicate Devices	Cordis Tempo™ Angiography Catheters (K973401)	
Classification	Class II.	
Performance Standards	Performance standards have not been established by the FDA under section 514 of the Food, Drug and Cosmetic Act.	
Intended Use and Device Description	Cordis Tempo Aqua Angiography Catheters are intended for the delivery of radiopaque contrast medium to selected sites in the vasculature.	
	The device description of Cordis Tempo Aqua Angiography Catheters is as follows:	
	The Tempo Aqua catheters are single lumen catheters consisting of Polyamide (body, intermediate and distal tip) and Polyurethane (brite tip) materials with a proximal strainrelief and hub. The catheters are available in various diameters and tip configurations. They are compatible with Guidewires with diameters of 0.035" and 0.038".	
Biocompatibility	All materials used in the Tempo Aqua Angiographic Catheters are biocompatible.	
Summary of Substantial	The Cordis Tempo <sup>™</sup> Aqua Angiography Catheters are substantially equivalent to the previously cleared Cordis Tempo Catheters.	

TEMPO Aqua Angiographic Catheter Special 510(k) Device Modification February, 2000

Equivalence



MAY - 3 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Ariel MacTavish Manager Regulatory Affairs Cordis Corporation P.O. Box 025700 Miami, FL 33102-5700

Re: K000579

Trade Name: Tempo $^{TM}$  Aqua Angiography Catheter

Regulatory Class: II (two)

Product Code: DQO .
Dated: March 30, 2000
Received: April 3, 2000

Dear Ms. MacTavish:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

James E. Dillard III

Director

Division of Cardiovascular and Respiratory Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

#### Attachment 2

# **Indications for Use Statement**

<b>510(k) Number</b> (if known)	K 000579		
Device Name	Tempo <sup>™</sup> Aqua Angiography Catheter		
Indications for Use	Cordis Tempo <sup>™</sup> Aqua Angiography Catheters are intended for the delivery of radiopaque contrast medium to selected sites in the vasculature.		
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED			
Concurrence of CDRH, Office of Device Evaluation (ODE)  (Division Sign-Off)  Division of Cardiovascular, Respiratory, and Neurological Devices  510(k) Number 600579			
Prescription U: (Per 21 CFR 80		Over-The-Counter Use	
TEMPO Aqua Special 510(k) February, 2000	Angiographic Catheter Device Modification		